Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
- 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
- Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
- Japan, South Korea Set Up Working Groups to Collaborate on Harmonization
May 16, 2017
- Procedures for Providing Unapproved Drugs to Developing Countries in Emergencies Could Become Finalized in June
May 15, 2017
- Transition Period of “at Least 1 Year” Needed for New Package Insert Format: MHLW
May 11, 2017
- Marketing Strategies for Participating Hospitals to Be Important for Drug Makers to Effectively Use MID-NET: PMDA Official
May 11, 2017
- LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
- Japan, US Ink Memorandum of Cooperation on Health
May 9, 2017
- Health Minister Shiozaki Stresses Importance of US-Japan Alliance in Healthcare
May 9, 2017
- Japan and India to Share Common View on Global Clinical Trials
May 9, 2017
- “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
- Experts Support Revision of Rules to Promote Concurrent Administration of Multiple Vaccines: MHLW Vaccine Panel
May 8, 2017
- MHLW Study Group Drafts “Items to Consider” to Promote Development of Nucleic Acid Drugs
May 2, 2017
- MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
- 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
- LDP Health Panel Holds Drug Pricing Hearing with Doctor, Pharmacist Groups
April 28, 2017
- Ad-Hoc Generic Prices for “Off-Year” Revisions Acceptable: Chuikyo Bill Payer Reps
April 27, 2017
- JMA’s Nakagawa Says MHLW Should Fuel Generic Industry Realignment: Chuikyo
April 27, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…